Introduction of Cabenphi as a Novel Antipsychotic

Cabenphi, a newly FDA-approved antipsychotic, marks a significant departure from traditional dopamine-blocking mechanisms. This medication, known as CAR-XT, combines xanomaline, a muscarinic agonist, and trospium, an anticholinergic agent. Xanomaline acts on M1 and M4 receptors, which are linked to cognitive functions and psychotic symptoms, providing a potential alternative treatment for schizophrenia. Unlike conventional antipsychotics, which often cause notable side effects like weight gain and fatigue, Cabenphi demonstrates a reduced likelihood of these adverse effects.